ProCE Banner Activity

How I Avoid Interactions Between Boosted ART and HCV Therapy in My Coinfected Patients

Case Challenge
Clinical Thought
Treatment of HCV/HIV coinfection requires continued awareness of and attention to the complex drug–drug interactions that can occur, especially when using pharmacologically boosted ARVs and nonnucleoside reverse transcriptase inhibitors. Here’s my take on how to approach drug–drug interactions using patient cases.

Released: January 25, 2019

Expiration: January 24, 2020

No longer available for credit.

Share

Faculty

Susanna Naggie

Susanna Naggie, MD

Infectious Diseases Fellow
Department of Internal Medicine, Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an independent educational grant from

Gilead

Faculty Disclosure

Primary Author

Susanna Naggie, MD

Infectious Diseases Fellow
Department of Internal Medicine, Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina

Susanna Naggie, MD, MHS, has disclosed that she has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Tacere.